Waters Corporation to Present at the TD Cowen Health Care Conference

MILFORD, Mass., Feb. 23, 2026 /PRNewswire/ -- Waters Corporation (NYSE:WAT) announced that Udit Batra, Ph.D.

PRNewsWire • Feb 23, 2026

Waters Introduces Next-Generation Microflow LC Columns with MaxPeak Premier Technology, Delivering Higher Sensitivity with Lower Sample and Solvent Usage

Headlines: Delivers up to 2× higher sensitivity than stainless steel microflow columns, lowering detection and quantitation limits across high-throughput bioseparations, DMPK, and 'omics applications.1  Uses up to 75% less sample than 2.1 mm I.D. columns, conserving precious materials such as cell and gene therapy and personalized medicine candidates while delivering deeper insights.

PRNewsWire • Feb 17, 2026

Waters Q4 Earnings Surpass Estimates, Revenues Increase Y/Y

WAT tops Q4 estimates as revenues rise 7% Y/Y, with strong Pharma and Europe growth, and upbeat 2026 sales and earnings outlook.

Zacks Investment Research • Feb 13, 2026

Down 19.0% in 4 Weeks, Here's Why Waters (WAT) Looks Ripe for a Turnaround

Waters (WAT) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

Zacks Investment Research • Feb 13, 2026

BD Merges Biosciences & Diagnostics Business With Waters

BDX completes its Biosciences & Diagnostic spin-off and Waters merger, securing $4B in proceeds as it pivots to a pure-play MedTech focus.

Zacks Investment Research • Feb 11, 2026

Waters Corporation (WAT) Q4 2025 Earnings Call Transcript

Waters Corporation (WAT) Q4 2025 Earnings Call Transcript

Seeking Alpha • Feb 9, 2026

Waters Corporation (NYSE: WAT) Reports Fourth Quarter and Full-Year 2025 Financial Results

Highlights Fourth Quarter 2025 Sales of $932 million landed at the high-end of reported sales growth guidance range; grew 7% as reported and 6% in constant currency Growth led by high single-digit constant currency growth in Pharma and Industrial end-markets, with broad-based growth across all regions Chemistry grew 12% in constant currency as new bioseparations products continued to experience significant customer demand Instruments grew 3% in constant currency, with high single-digit LC-MS growth partially offset by TA and transition to subscription model for Empower GAAP EPS of $3.77; non-GAAP EPS of $4.53 grew double digits Full-Year 2025 Sales of $3,165 million grew 7% as reported and 7% in constant currency Instruments grew 5% in constant currency, led by strong LC-MS growth Recurring Revenue grew 8% in constant currency, led by 12% Chemistry growth GAAP EPS of $10.76; non-GAAP EPS of $13.13 grew double digits MILFORD, Mass., Feb. 9, 2026 /PRNewswire/ -- Waters Corporation (NYSE: WAT), today announced its financial results for the fourth quarter and full year 2025.

PRNewsWire • Feb 9, 2026

Why Is Waters Stock Sinking Monday?

Waters Corporation (NYSE: WAT) stock is trading lower on Monday after the company released fourth-quarter 2025 financial results and issued fiscal 2026 guidance.

Benzinga • Feb 9, 2026

Waters (WAT) Beats Q4 Earnings and Revenue Estimates

Waters (WAT) came out with quarterly earnings of $4.53 per share, beating the Zacks Consensus Estimate of $4.5 per share. This compares to earnings of $4.1 per share a year ago.

Zacks Investment Research • Feb 9, 2026

Waters Completes Combination with BD's Biosciences & Diagnostic Solutions Businesses

Announces appointment of Claire M. Fraser, Ph.D.

PRNewsWire • Feb 9, 2026